Home/Filings/4/0001104659-22-098949
4//SEC Filing

Bashan Dror 4

Accession 0001104659-22-098949

CIK 0001006281other

Filed

Sep 8, 8:00 PM ET

Accepted

Sep 9, 5:02 PM ET

Size

6.0 KB

Accession

0001104659-22-098949

Insider Transaction Report

Form 4
Period: 2022-09-07
Bashan Dror
DirectorPRESIDENT AND CEO
Transactions
  • Award

    Stock Options (Right to Buy)

    2022-09-07+750,000750,000 total
    Exercise: $1.03Exp: 2032-09-07Common Stock (750,000 underlying)
Footnotes (2)
  • [F1]The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
  • [F2]Does not include options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029.

Issuer

Protalix BioTherapeutics, Inc.

CIK 0001006281

Entity typeother

Related Parties

1
  • filerCIK 0001781450

Filing Metadata

Form type
4
Filed
Sep 8, 8:00 PM ET
Accepted
Sep 9, 5:02 PM ET
Size
6.0 KB